Abstract 15281: Cd34+ Cell Therapy Significantly Reduces Adverse Cardiacevents and Healthcare Expenditures in Patients With Refractory Angina
Delivery of CD34 stem cells to patients with refractory angina has been shown to improve exercise time, decrease angina frequency and mortality compared to placebo at 12 months. However, a comparison of cardiac events experienced in the 12 months pre- and post-treatment has not been conducted. Addit...
Saved in:
| Published in: | Circulation (New York, N.Y.) Vol. 138; no. Suppl_1 Suppl 1; p. A15281 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
by the American College of Cardiology Foundation and the American Heart Association, Inc
06-11-2018
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Delivery of CD34 stem cells to patients with refractory angina has been shown to improve exercise time, decrease angina frequency and mortality compared to placebo at 12 months. However, a comparison of cardiac events experienced in the 12 months pre- and post-treatment has not been conducted. Additionally, the influence of CD34 therapy on healthcare expenditures is unknown. We sought to determine whether subjects who received stem cell therapy experienced fewer cardiac events during the 12 months following CD34 cell therapy than during the 12 months prior to injection, and whether a reduction in events was associated with a cost savings within the first year after treatment. Cardiac-related hospital and ED events and revascularizations were retrospectively tabulated from electronic medical records for subjects enrolled in one of three CD34 trials sponsored by Baxter Healthcare (Deerfield, IL). Health expenditures before and after cell therapy were tabulated using the Healthcare Cost and Utilization Project. Between 2004 and 2011, a total of 62 subjects at a single institution were randomized to CD34 therapy (1.0 to 5.0 x 10 cells / kg) (n=39) vs. placebo (n=19) or standard of care (n=4). On average, patients randomized to cell therapy experienced 1.49 ± 1.30 cardiac-related events in the 12 months prior to injection, compared to 0.69 ± 1.20 events in the 12 months after intramyocardial stem cell injections (p < 0.01). This reduction in total events was associated with a cost savings of $12,404 per patient. Since enrollment began, a total of 37% of patients randomized to placebo (n=7) have died compared to 20% of patients randomized to CD34+ therapy (n=8).ConclusionCD34 stem cell therapy for patients with refractory angina ineligible for further revascularization is associated with fewer hospital admissions for cardiac events and is associated with significant savings in healthcare expenditures. |
|---|---|
| ISSN: | 0009-7322 1524-4539 |